Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

UC Berkeley’s SkyDeck accelerator has secured an exit as schoolwork assessment technology developer Gradescope was acquired by Turnitin.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

This is our data snapshot based on last month’s investment activity. 
The charts and tables have been generated by our data platform GCV Analytics.

The following is a snapshot of the data we have collected on investment activity over the past three months. To verify reported deals, we contact about 300 corporate investors each quarter – these comprise roughly 18% of the global CVCs we cover, but account for most of the deals that are made public.

The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

Dell Technologies Capital will exit Redlock in an acquisition by Palo Alto Networks, five months after it bought another cloud security software developer.

Anju Software has paid an undisclosed sum to acquire healthcare data provider Zephyr Health, which had raised $33.5m from investors including GV.